Compagnie Lombard Odier SCmA
Position in MDGL — Madrigal Pharmaceuticals, Inc.
CIK 1615423
1204 GENEVA, V8
Position in MDGL
as of Jun 30, 2026
· filed Jul 29, 2026
Position Value
$0
-$12,563 QoQ
Shares Held
0
-100.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
10 quarters on record
Common Shares in MDGL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Compagnie Lombard Odier SCmA holds $19,084,552 across 11 Biotechnology names. MDGL ranks #11 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRNA |
Moderna, Inc.
|
111,582 | $7,814,087 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
13,065 | $6,489,777 | |
| 3 | OCS |
Oculis Holding AG
|
105,455 | $1,462,660 | |
| 4 | VKTX |
Viking Therapeutics, Inc.
|
30,245 | $1,179,857 | |
| 5 | LXRX |
Lexicon Pharmaceuticals, Inc.
|
480,000 | $1,152,000 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
550 | $342,947 | |
| 7 | BNTX |
BioNTech SE
|
3,560 | $331,258 | |
| 8 | RPRX |
Royalty Pharma plc
|
2,900 | $162,603 |
All Filings in MDGL
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0 | 0 | Shares | Defined | 2026-07-29 | |
| 2026-03-31 | $12,563 | 24 | Shares | Defined | 2026-04-15 | |
| 2025-12-31 | $13,976 | 24 | Shares | Defined | 2026-01-16 | |
| 2025-09-30 | $47,700 | 104 | Shares | Defined | 2025-11-06 | |
| 2025-06-30 | $31,474 | 104 | Shares | Defined | 2025-07-15 | |
| 2025-03-31 | $34,447 | 104 | Shares | Defined | 2025-04-16 | |
| 2024-12-31 | $32,091 | 104 | Shares | Defined | 2025-01-30 | |
| 2024-09-30 | $22,070 | 104 | Shares | Defined | 2024-10-11 | |
| 2024-06-30 | $29,136 | 104 | Shares | Defined | 2024-07-18 | |
| 2024-03-31 | $21,363 | 80 | Shares | Defined | 2024-05-01 | |
| No filing history on record for this holder in this stock. | ||||||